Loading...
Market
Story
Moderna Surpasses Q3 Estimates with $1.86B Revenue, $1.8B COVID Vaccine Sales, and $0.03 EPS
Nov 7, 2024, 11:57 AM
Moderna Inc. (MRNA) reported its third-quarter 2024 financial results, announcing revenue of $1.86 billion, exceeding the estimated $1.25 billion. The company's COVID-19 vaccine revenue was $1.8 billion, surpassing the estimated $1.2 billion, including $1.8 billion in Spikevax sales. Moderna achieved a net income of $13 million, compared to a net loss of $3.6 billion in the same period last year, resulting in earnings per share (EPS) of $0.03, outperforming the expected loss per share of $1.90. The company reported RSV vaccine revenue of $10 million. Moderna reiterated its 2024 expected product sales of $3.0 to $3.5 billion and year-to-date product sales of $2.2 billion. Cash and cash equivalents were reported at $9.2 billion.
View original story
Similar markets
Less than $3 billion • 25%
$3 billion to $3.5 billion • 25%
$3.5 billion to $4 billion • 25%
More than $4 billion • 25%
Outperforms S&P 500 • 25%
Matches S&P 500 • 25%
Underperforms S&P 500 • 25%
Declines • 25%
Decrease by more than 10% • 25%
Change between -10% and 10% • 25%
Increase by 10% to 20% • 25%
Increase by more than 20% • 25%
Below $3.60 • 25%
$3.60 to $3.75 • 25%
$3.76 to $3.90 • 25%
Above $3.90 • 25%
COVID-19 Vaccine • 25%
RSV Vaccine • 25%
Other Products • 25%
No clear top-seller • 25%
Below $10.00 • 25%
$10.00 - $10.24 • 25%
$10.25 - $10.49 • 25%
$10.50 or higher • 25%
$2.80 - $2.85 • 25%
$2.86 - $2.90 • 25%
$2.91 - $2.95 • 25%
$2.96 - $3.00 • 25%
Below $16.10 • 25%
$16.10 to $16.60 • 25%
$16.61 to $17.10 • 25%
Above $17.10 • 25%